A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

被引：0
作者：
N. Masuda
K. Higaki
T. Takano
N. Matsunami
T. Morimoto
S. Ohtani
M. Mizutani
T. Miyamoto
K. Kuroi
S. Ohno
S. Morita
M. Toi
机构：
[1] National Hospital Organization Osaka National Hospital,Department of Surgery, Breast Oncology
[2] Hiroshima City Hospital,Tokyo Metropolitan Cancer and Infectious Diseases Center
[3] Toranomon Hospital,Clinical Research Center
[4] Osaka Rousai Hospital,undefined
[5] Yao Municipal Hospital,undefined
[6] Gunma Prefectural Cancer Center,undefined
[7] Komagome Hospital,undefined
[8] National Hospital Organization Kyushu Cancer Center,undefined
[9] Yokohama City University Medical Center,undefined
[10] Graduate School of Medicine Kyoto University,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Triple-negative breast cancer; Metronomic chemotherapy; Weekly paclitaxel; Oral cyclophosphamide; Capecitabine; pCR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：229 / 238
页数：9
相关论文
共 50 条
  • [1] A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer
    Masuda, N.
    Higaki, K.
    Takano, T.
    Matsunami, N.
    Morimoto, T.
    Ohtani, S.
    Mizutani, M.
    Miyamoto, T.
    Kuroi, K.
    Ohno, S.
    Morita, S.
    Toi, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 229 - 238
  • [2] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Masataka Yoshimoto
    Shintaro Takao
    Masaru Hirata
    Yasushi Okamoto
    Sumio Yamashita
    Yoshihiro Kawaguchi
    Makoto Takami
    Hidemi Furusawa
    Satoshi Morita
    Chigusa Abe
    Junichi Sakamoto
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 331 - 338
  • [3] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Yoshimoto, Masataka
    Takao, Shintaro
    Hirata, Masaru
    Okamoto, Yasushi
    Yamashita, Sumio
    Kawaguchi, Yoshihiro
    Takami, Makoto
    Furusawa, Hidemi
    Morita, Satoshi
    Abe, Chigusa
    Sakamoto, Junichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 331 - 338
  • [4] Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
    Liu, Yin
    Fan, Lei
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    ONCOLOGIST, 2023, 28 (01) : 86 - +
  • [5] Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide
    Sun, Weiling
    Li, Chunhong
    Liu, Meiyan
    Liu, Wei
    Yang, Chunyu
    Cai, Li
    ONCOLOGY LETTERS, 2016, 11 (03) : 2320 - 2326
  • [6] A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer
    Jinno, H.
    Sakata, M.
    Hayashida, T.
    Takahashi, M.
    Mukai, M.
    Ikeda, T.
    Kitagawa, Y.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1262 - 1266
  • [7] Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
    Ando, Masashi
    Yamauchi, Hideko
    Aogi, Kenjiro
    Shimizu, Satoru
    Iwata, Hiroji
    Masuda, Norikazu
    Yamamoto, Naohito
    Inoue, Kenichi
    Ohono, Shinji
    Kuroi, Katsumasa
    Hamano, Tetsutaro
    Sukigara, Tamie
    Fujiwara, Yasuhiro
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (02) : 401 - 409
  • [8] Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial
    Tokunaga, Shinya
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Kawajiri, Hidemi
    Tokumoto, Mao
    Nishimura, Shigehiko
    Nishimori, Takeo
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Yamagata, Shigehito
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2019, 39 (04) : 2053 - 2059
  • [9] Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
    Zhang, Minmin
    Wei, Wei
    Liu, Jianlun
    Yang, Huawei
    Jiang, Yi
    Tang, Wei
    Li, Qiuyun
    Liao, Xiaoming
    ONCOTARGETS AND THERAPY, 2016, 9 : 3443 - 3450
  • [10] Combinatorial Effects of Chrysin with Doxorubicin, 5-Fluorouracil, and Cyclophosphamide on Triple-Negative Breast Cancer Cell Line
    Yosefi, Sedighe
    Madanchi, Hamid
    Pakdel, Abbas
    Kokhaei, Parviz
    Hemati, Maral
    Sarmadi, Negar
    Sirati-Sabet, Majid
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2025, 24 (01):
12345